

NORTHERN ARIZONA CLINICAL TRIALS

Breast Cancer

Cape+BKMI20 TNBC BC Brain met
Phase II Multicenter Single-arm Study of BKM120 plus
Capecitabine for Triple Negative Breast Cancer (TNBC)
Patients with Brain Metastases

Ruxolitinib/placeb+Cape met HER2- Breast
A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or
Placebo in Combination With Capecitabine in Subjects With
Advanced or Metastatic HER2-Negative Breast Cancer (INCB
18424-268)

SystHERs HER2+ Breast Observational
An Observational Cohort Study of Treatment Patterns and
Outcomes in Patients with HER2 Positive (HER2+) Metastatic
Breast Cancer

Palbociclib Post AI HR+HER2- MBC
Multicenter, Randomized, Double-Blind, Placebo-Controlled,
Phase III Trial of Fulvestrant (Faslodex®) with or without
PD-0332991 Palbociclib)± Goserelin in Women with Hormone
Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Whose Disease Progressed After Prior Endocrine Therapy

BMN673 vs PhyChoice gBRCA met Br
A Phase III, Open-Label, Randomized, Parallel, 2-Arm,
Multi-Center Study of BMN 673 Versus Physician's Choice in
Germline BRCA Mutation Subjects with Locally Advanced
and/or Metastatic Breast Cancer, Who Have Received No More
than 2 Prior Chemotherapy Regimens for Metastatic Disease

MONALEESA2 LEE011+Letr Postmen HR+HER2-
A Randomized Double-Blind, Placebo-Controlled Study of
LEE011 in Combination with Letrozole for the Treatment of
Postmenopausal Women with Hormone Receptor Positive,
HER2-Negative, Advanced Breast Cancer who Received no
Prior Therapy for Advanced Disease

Niraparib vs PhyChoice HER2-gBRCA Breast
A Phase III, Randomized, Open Label, Multicenter, Controlled
Trial of Niraparib Versus Physician's Choice in Previously-
Treated, HER2 Negative, Germline BRCA Mutation-Positive
Breast Cancer Patients

Gynecologic Cancer

Trabectedin +/- PLD Adv Ovarian 2/3 In
A Randomized, Open-Label Study Comparing the
Combination of YONDELIS® and DOXIL®/CAELYX® With
DOXIL®/CAELYX® Monotherapy for the Treatment of
Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or
Fallopian Tube Cancer

Leukemia

CML Observational Trial - SIMPLICITY
Studying Interventions for Managing Patients with Chronic
Myeloid Leukemia in Chronic Phase: The 5-Year Prospective
Cohort Study (SIMPLICITY)

Lung Cancer

Nivolumab for Sqm or Non-Sqm NSCLC
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in
Subjects with Advanced or Metastatic Non-Small Cell Lung
Cancer Who Have Progressed During or After Receiving At
Least One Prior Systemic Regimen (CA209153)

Docetaxel +/- Ganetespib NSCLC
A Randomized, Phase 3 Study of Ganetespib in Combination
with Docetaxel versus Docetaxel Alone in Patients with
Advanced Non-Small-Cell Lung Adenocarcinoma

LDK378 v SOC ALK+ NSCLC Post Chemo/Criz
A Phase III, Multicenter, Randomized, Open-Label Study of
Oral LDK378 Versus Standard Chemotherapy in Adult Patients
with ALK-Rearranged (ALK-Positive) Advanced Non-Small
Cell Lung Cancer Who Have Been Treated Previously with
Chemotherapy (Platinum Doublet) and Crizotinib

Prostate Cancer

XL184 +Abiraterone w Bone Mets in cRPC
A Randomized Phase II Study of Cabozantinib (XL184) in
Combination with Abiraterone in Chemotherapy Naive
Subjects with Bone-Metastatic Castration-Resistant
Prostate Cancer

Hematologic & Solid Tumors

PI3K Activated Tumor
Modular Phase II Study to Link Targeted Therapy to Patients
with Pathway Activated Tumors: Module 1 - BKM120 for
Patients with PI3K-Activated Tumors

FCFR Activated Tumor
Modular Phase II Study to Link Targeted Therapy to Patients
with Pathway Activated Tumors: Module 2 - Dovitinib for
Patients with Tumor Pathway Activations Inhibited by
Dovitinib Including tumors with Mutations or Translocations
of FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET

Signature Series: RAS/RAF/MEK tumors
Modular Phase II Study to Link Targeted Therapy to Patients
with Pathway Activated Tumors: Module 3 - MEK162 for
Patients with RAS/RAF/MEK activated tumors

**For more information or to refer a patient,
call 855-234-HEAL.**

